Vitality Watch

Dossier clinicaltrials trial early 15-jul-2026
Small or early-phase human trial or pilot study

Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome

Key claim: A Phase I open-label study is testing the safety and tolerability of intravenous allogeneic umbilical cord–derived mesenchymal stem cells (MiraMSC-FS-001) in older adults with mild to moderate frailty syndrome.

Abstract

The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.

Why this matters

A Phase I open-label study is testing the safety and tolerability of intravenous allogeneic umbilical cord–derived mesenchymal stem cells (MiraMSC-FS-001) in older adults with mild to moderate frailty syndrome.

Source

Link

Briefing card

Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
Stage: trial early · clinicaltrials · 15-jul-2026

A Phase I open-label study is testing the safety and tolerability of intravenous allogeneic umbilical cord–derived mesenchymal stem cells (MiraMSC-FS-001) in older adults with mild to moderate frailty syndrome.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07705464

build build 880 · 2bcef25 · 2026-11-18